Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.46 |
| ▸ | HTR1A | P08908 | 2/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.44 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 2/20 | 0.41 |
| ▸ | HTR2B | P41595 | 2/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23830994 | 1.00 | CHRNB2 (0.46) | CHRNB2CHRNA4HTR1ASLC6A2PRKCZ | |
| Methane SCHEMBL29003897 | 0.98 | CHRNB2 (0.45) | CHRNB2CHRNA4HTR1ASLC6A2PRKCZ | |
| SCHEMBL940760 | 0.89 | HRH1 (0.43) | HTR1ASLC6A2 | |
| SCHEMBL9900853 | 0.85 | SLC6A2 (0.41) | HTR1ASLC6A2HTR2CHTR2BCHRM1 | |
| Hydrochloric Acid SCHEMBL4114449 | 0.84 | SLC6A2 (0.40) | HTR1ASLC6A2HTR2CHTR2BCHRM1 | |
| SCHEMBL29003876 | 0.83 | CHRNB2 (0.46) | CHRNB2CHRNA4PRKCZHTR2CHTR2B | |
| SCHEMBL29003843 | 0.83 | CHRNB2 (0.46) | CHRNB2CHRNA4PRKCZHTR2CHTR2B | |
| SCHEMBL25072464 | 0.82 | CHEK1 (0.45) | CHRNB2CHRNA4HTR1ASLC6A2PRKCZ | |
| SCHEMBL7889387 | 0.80 | CHRNB2 (0.54) | CHRNB2CHRNA4HTR1ASLC6A2PRKCZ | |
| SCHEMBL4102786 | 0.80 | CHRNB2 (0.54) | CHRNB2CHRNA4HTR1ASLC6A2PRKCZ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108456204-B | Benzothiazine derivative, and preparation method and application thereof | 四川大学 | 2023-05-26 | — | — | CN | disclosed |
| US-20210292305-A1 | Cyclic Ureas | SIRONAX LTD (KY) | 2021-09-23 | — | — | US | disclosed |
| US-20210292305-A1 | Cyclic Ureas | SIRONAX LTD (KY) | 2021-09-23 | — | — | US | disclosed |
| CN-113302183-A | Cyclic ureas | 圣瑞诺有限公司 | 2021-08-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210292305-A1 | Cyclic Ureas | RIPK1, RIPK3, RIPK4 | CHRNB2 4728/4885CHRNA4 4607/4885HTR1A 2665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.